Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk

Abstract

On the basis of large randomized clinical trials, pharmacological antagonists of HMG-CoA reductase (statins) have become increasingly used in clinical practice for the prevention of cardiovascular disease. Rosuvastatin was developed as a potent statin, which appeared to raise levels of HDL-cholesterol, in addition to marked reductions in levels of LDL-cholesterol. These effects on lipids are associated with a beneficial impact of rosuvastatin on progression of various stages of atherosclerosis and cardiovascular outcomes in clinical trials. The clinical experience of rosuvastatin will be reviewed in this article.

Keywords::

• atherosclerosis
• cardiovascular disease
• clinical trials
• lipids
• risk factors
• rosuvastatin

Financial & competing interests disclosure

Stephen J Nicholls has received research support from AstraZeneca, Novartis, Eli Lilly, Resverlogix, Anthera, Roche, LipoScience and Karo Bio, and consulting fees/honoraria from AstraZeneca, Merck, Takeda, Roche, Omthera, sanofi-aventis, CSL Behring and Boehringer Ingelheim. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.